Hutchmed (China) (0013) said China’s National Medical Products Administration has granted conditional approval for a new drug application for ORPATHYS (savolitinib), according to Ming Pao. The company said the approval is for treating adult patients with locally advanced or metastatic gastric cancer or gastroesophageal junction (GC/GEJ) adenocarcinoma with MET gene amplification who have failed at least two systemic therapies.